Michael A Gorin1, Steven P Rowe2, Alexander S Baras3, Lilja B Solnes2, Mark W Ball1, Phillip M Pierorazio1, Christian P Pavlovich1, Jonathan I Epstein4, Mehrbod S Javadi2, Mohamad E Allaf5. 1. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: mallaf@jhmi.edu.
Abstract
UNLABELLED: Nuclear imaging offers a potential noninvasive means of determining the histology of renal tumors. The aim of this study was to evaluate the accuracy of technetium-99m ((99m)Tc)-sestamibi single-photon emission computed tomography/x-ray computed tomography (SPECT/CT) for the differentiation of oncocytomas and hybrid oncocytic/chromophobe tumors (HOCTs) from other renal tumor histologies. In total, 50 patients with a solid clinical T1 renal mass were imaged with (99m)Tc-sestamibi SPECT/CT prior to surgical resection. Preoperative SPECT/CT scans were reviewed by two blinded readers, and their results were compared with centrally reviewed surgical pathology data. Following surgery, 6 (12%) tumors were classified as renal oncocytomas and 2 (4%) as HOCTs. With the exception of 1 (2%) angiomyolipoma, all other tumors were renal cell carcinomas (82%). (99m)Tc-sestamibi SPECT/CT correctly identified 5 of 6 (83.3%) oncocytomas and 2 of 2 (100%) HOCTs, resulting in an overall sensitivity of 87.5% (95% confidence interval [CI], 47.4-99.7%). Only two tumors were falsely positive on SPECT/CT, resulting in a specificity of 95.2% (95% CI, 83.8-99.4%). In summary, (99m)Tc-sestamibi SPECT/CT is a promising imaging test for the noninvasive diagnosis of renal oncocytomas and HOCTs. PATIENT SUMMARY: We found that the imaging test (99m)Tc-sestamibi SPECT/CT can be used to accurately diagnose two types of benign kidney tumors. This test may be eventually used to help better evaluate patients diagnosed with a renal tumor.
UNLABELLED: Nuclear imaging offers a potential noninvasive means of determining the histology of renal tumors. The aim of this study was to evaluate the accuracy of technetium-99m ((99m)Tc)-sestamibi single-photon emission computed tomography/x-ray computed tomography (SPECT/CT) for the differentiation of oncocytomas and hybrid oncocytic/chromophobe tumors (HOCTs) from other renal tumor histologies. In total, 50 patients with a solid clinical T1 renal mass were imaged with (99m)Tc-sestamibi SPECT/CT prior to surgical resection. Preoperative SPECT/CT scans were reviewed by two blinded readers, and their results were compared with centrally reviewed surgical pathology data. Following surgery, 6 (12%) tumors were classified as renal oncocytomas and 2 (4%) as HOCTs. With the exception of 1 (2%) angiomyolipoma, all other tumors were renal cell carcinomas (82%). (99m)Tc-sestamibi SPECT/CT correctly identified 5 of 6 (83.3%) oncocytomas and 2 of 2 (100%) HOCTs, resulting in an overall sensitivity of 87.5% (95% confidence interval [CI], 47.4-99.7%). Only two tumors were falsely positive on SPECT/CT, resulting in a specificity of 95.2% (95% CI, 83.8-99.4%). In summary, (99m)Tc-sestamibi SPECT/CT is a promising imaging test for the noninvasive diagnosis of renal oncocytomas and HOCTs. PATIENT SUMMARY: We found that the imaging test (99m)Tc-sestamibi SPECT/CT can be used to accurately diagnose two types of benign kidney tumors. This test may be eventually used to help better evaluate patients diagnosed with a renal tumor.
Authors: Nicholas J Farber; Christopher J Kim; Parth K Modi; Jane D Hon; Evita T Sadimin; Eric A Singer Journal: Transl Cancer Res Date: 2017-06 Impact factor: 1.241
Authors: Scott P Campbell; Antonios Tzortzakakis; Mehrbod S Javadi; Mattias Karlsson; Lilja B Solnes; Rimma Axelsson; Mohamad E Allaf; Michael A Gorin; Steven P Rowe Journal: Br J Radiol Date: 2018-02-27 Impact factor: 3.039
Authors: Julie Y An; Mark W Ball; Michael A Gorin; Jiwon J Hong; Michael H Johnson; Christian P Pavlovich; Mohamad E Allaf; Phillip M Pierorazio Journal: Urology Date: 2016-11-23 Impact factor: 2.649
Authors: Jay Amin; Bo Xu; Shervin Badkhshan; Terrance T Creighton; Daniel Abbotoy; Christine Murekeyisoni; Kristopher M Attwood; Thomas Schwaab; Craig Hendler; Michael Petroziello; Charles L Roche; Eric C Kauffman Journal: Clin Cancer Res Date: 2018-05-11 Impact factor: 12.531
Authors: Akrita Bhatnagar; Steven P Rowe; Michael A Gorin; Martin G Pomper; Elliot K Fishman; Mohamad E Allaf Journal: J Comput Assist Tomogr Date: 2016 Jul-Aug Impact factor: 1.826
Authors: Hiten D Patel; Emmanuel Iyoha; Phillip M Pierorazio; Stephen M Sozio; Michael H Johnson; Ritu Sharma; Eric B Bass; Mohamad E Allaf Journal: Urology Date: 2016-08-16 Impact factor: 2.649